Immunotherapy: Controlled attack.
Charles
C
Schmidt
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D015415:Biomarkers; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D008297:Male; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics / Q000276:immunology; D000077594:Nivolumab; D011379:Prognosis; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D019496:Cancer Vaccines; D000074324:Ipilimumab; D000077594:Nivolumab